精神分裂症青少年患者对于阿立哌唑的早期抗精神病反应:对于临床结局的提示价值
OBJECTIVE:
In adults with chronic schizophrenia, most symptom decreases occur in the first few weeks of antipsychotic treatment, and nonresponse at week 2 predicts a later nonresponse. The trajectory of antipsychotic response and the predictive value of early antipsychotic effects were investigated for ultimate outcome in adolescent schizophrenia, where such data are still lacking.
METHOD:
This post hoc analysis of a 6-week, randomized, double-blinded trial of aripiprazole (n = 196) versus placebo (n = 98) evaluated ifadolescents 13 to 17 years old with schizophrenia exhibited substantial symptomatic improvement to aripiprazole in the first few treatment weeks and whether early response (ER) versus early nonresponse (ENR) predicted clinically relevant outcomes. ER decreased at least 20% and ENR decreased less than 20% in Positive and Negative Syndrome Scale (PANSS) total score at week 2 (ER2/ENR2) or 3 (ER3/ENR3). Ultimate response decreased at least 40% in PANSS score.
RESULTS:
Nearly 50% of the PANSS decrease was achieved by week 2 and up to 75% by week 3. ER2/ER3 subjects showed significantly greater improvement than ENR subjects in PANSS total score, PANSS positive and negative subscale scores, and functionally relevant outcomes. In general, ER3 had better sensitivity, specificity, and positive and negative predictive values than ER2 for predicting ultimate response. ER2 subjects were 8.8 times (95% confidence interval 4.0-19.4) and ER3 subjects were 8.6 times (95% confidence interval 4.5-16.6) more likely to achieve remission at week 6 (p < .0001) than ENR2 and ENR3 subjects, respectively, although adverse events were similar.
CONCLUSIONS:
Like adults with chronic schizophrenia, adolescents with early-phase schizophrenia exhibited most symptomatic improvement earlyduring aripiprazole treatment, with week 3 improvements having the best predictive power. Although requiring extension, these results may informclinical decision making. Clinical trial registration information-Aripiprazole in Adolescents with Schizophrenia, http://clinicaltrials.gov/, NCT00102063.
上一篇: ALK重排的NSCLC的诊断和治疗
下一篇: 普拉格雷5 mg用于极高龄患者的血小板抑制效果稍弱但且疗效不劣于10 mg应用于非高龄患者:一项针对冠心病患者的药效学和药动学研究(GENERATIONS试验)
- 您可能感兴趣的文章
-